| Literature DB >> 29615930 |
Chang Liu1,2,3, Bao Liu1,2,3,4, Lu Liu1,2,3, Er-Long Zhang1,2,3, Bind-da Sun1,2,3, Gang Xu1,2,3, Jian Chen1,2,3, Yu-Qi Gao1,2,3.
Abstract
Background: The modulation of arachidonic acid (AA) metabolism pathway is identified in metabolic alterations after hypoxia exposure, but its biological function is controversial. We aimed at integrating plasma metabolomic and transcriptomic approaches to systematically explore the roles of the AA metabolism pathway in response to acute hypoxia using an acute mountain sickness (AMS) model.Entities:
Keywords: WGCNA; arachidonic acid; hypoxia; metabolomics; transcriptomics
Year: 2018 PMID: 29615930 PMCID: PMC5864929 DOI: 10.3389/fphys.2018.00236
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
Figure 1Baseline clinical characteristics of SpO2 (A), HR (B), SBP (C), DBP (D), HB (E), and LLS (F) for enrolled subjects before and after high altitude exposure. Statistical significance is indicated as *p < 0.05.
Figure 2Metabolic profiling analysis in response to acute hypoxia exposure. (A) WGCNA analysis identified four connectivity-based modules with high correlation to clinic features of heart rate (HR), oxygen saturation (SpO2), Lake Louise score (LLS), systolic blood pressure (SBP), diastolic blood pressure (DBP), and hemoglobin (HB). High correlation values are indicated by red and negative correlations, in green color. (B) Comparison of all metabolites from plasma of subjects before and after hypoxia exposure. The volcano plot displays the relationship between fold change and significance using a scatter plot view. The green points in the plot represent the differential metabolites with statistical significance. (C) Enrichment pathway analysis for the dominant metabolites identified in the volcano plot before and after hypoxia exposure.
Summary of the influential metabolites in 53 subjects at high altitude relative to plain.
| 12-Oxo-trihydroxy-leukotriene B4 | 2.04E-07 | 0.26 | 2.29 |
| Bilirubin | 1.57E-07 | 0.33 | 3.26 |
| Undecanoylcarnitine | 8.49E-12 | 0.37 | 1.75 |
| 15(S)-HETE | 2.06E-05 | 0.40 | 1.85 |
| Oleic acid | 1.85E-08 | 0.41 | 4.47 |
| L-Hexanoylcarnitine | 8.01E-08 | 0.42 | 1.84 |
| Ceramide (d18:1/16:0) | 4.99E-11 | 0.43 | 2.20 |
| 15-Deoxy-d-12,14-PGJ2 | 4.84E-08 | 0.44 | 1.60 |
| 3, 5-Tetradecadiencarnitine | 1.38E-06 | 0.45 | 2.33 |
| 20-Hydroxy-leukotriene E4 | 2.89E-09 | 0.45 | 1.57 |
| Pimelylcarnitine | 3.49E-08 | 0.48 | 2.23 |
| 3-hydroxydecanoyl carnitine | 4.50E-09 | 0.48 | 2.25 |
| 9-Hexadecenoylcarnitine | 5.37E-09 | 0.48 | 2.07 |
| Dodecanoylcarnitine | 2.75E-07 | 0.50 | 2.15 |
| Decanoylcarnitine | 2.35E-06 | 0.53 | 2.60 |
| Tetradecanoylcarnitine | 1.23E-07 | 0.54 | 1.73 |
| trans-2-Dodecenoylcarnitine | 2.80E-07 | 0.54 | 2.28 |
| Linoleic acid | 4.28E-08 | 0.55 | 4.33 |
| DG(15:0/18:0/0:0) | 2.29E-07 | 0.55 | 1.90 |
| LysoPE(14:0/0:0) | 1.35E-08 | 0.57 | 2.98 |
| Palmitic acid | 1.23E-05 | 0.57 | 2.87 |
| N-methylphenylalanine | 7.75E-12 | 0.58 | 1.55 |
| Tiglylglycine | 1.02E-12 | 0.58 | 2.93 |
| 21-Hydroxypregnenolone | 8.95E-08 | 0.59 | 1.54 |
| L-Octanoylcarnitine | 5.25E-05 | 0.59 | 2.00 |
| Arachidonic acid | 1.17E-07 | 0.65 | 2.61 |
| Alpha-Linolenic acid | 8.90E-05 | 0.66 | 1.55 |
| LysoPC(20:2) | 6.82E-12 | 1.59 | 3.08 |
| LysoPC(P-18:0) | 2.57E-10 | 1.62 | 2.14 |
| LysoPC(20:0) | 6.09E-09 | 1.63 | 1.79 |
| LysoPE(0:0/22:0) | 2.17E-11 | 1.63 | 2.26 |
| Stearoylcarnitine | 1.22E-06 | 1.66 | 2.26 |
| Glycocholic acid | 1.14E-08 | 1.69 | 2.62 |
| Deoxyinosine | 3.28E-11 | 1.83 | 1.74 |
| Deoxyribose 1-phosphate | 1.92E-06 | 1.87 | 1.69 |
| LysoPC(18:2(9Z,12Z)) | 1.23E-15 | 2.07 | 2.346 |
Figure 3Integrated analysis of metabolomic and transcriptomic profiling. (A) Unsupervised hierarchical cluster of correlation coefficients (kME and normalized metabolite values). High correlations are colored in red and low correlations, in green. (B) GO analysis for the modules inside the violet frame. (C) Network visualization of genes with high correlations to the AA metabolism pathway.
Figure 4Schematic overview of the AA metabolism pathway. The alterations in metabolites are shown in a blue frame (plain VS plateau), while the changes between adaptation(Ada) subjects and maladaptation(Mal) individuals to hypoxia are presented in a red box. The yellow triangle indicates the key enzymes validated in another cohort. The metabolites labeled by a dotted box represent no detection. Statistical significance is indicated as *p < 0.05.
Figure 5Validation of the AA metabolism pathway in another cohort. The genes of PTGES (A), PTGS1 (B), GGT1 (C), TBXAS1 (D), CBR1 (E), ALOX5 (F), ALOX15B (G), PLA2 (H) were significantly up-regulated in those who exhibited mal-adaptation to high altitude exposure. Statistical significance is indicated as *p < 0.05.